Durvalumab Drug Aliquot | Anti-PD-L1 | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Durvalumab are now available as research consumables.

Durvalumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Durvalumab drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Imfinzi Durvalumab Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Imfinzi® / Durvalumab Reference Product

Drug nameImfinzi®
INNDurvalumab
API typeDurvalumab is a human monoclonal IgG1κ antibody
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
L01XC28
Target of antibody
PD-L1
Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1,
Pdcd1lg1, Pdl1, RGD1566211
General functionDurvalumab, is a monoclonal antibody, a type of protein designed to recognize and attach to a protein called ‘programmed death-ligand 1’ (PD-L1), which is present on the surface of many cancer cells, produced in Chinese hamster Ovary (CHO) cells.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Expression of programmed cell death ligand-1 (PD-L1) protein is an adaptive immune response that helps tumours evade detection and elimination by the immune system. PD-L1 can be induced by inflammatory signals (e.g., IFN-gamma) and can be expressed on both tumour cells and 13 tumour-associated immune cells in the tumour microenvironment. PD-L1 blocks T-cell function and activation through interaction with PD-1 and CD80 (B7.1). By binding to its receptors, PD-L1 reduces cytotoxic T-cell activity, proliferation and cytokine production.
Durvalumab is a fully human, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that selectively blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1).
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Durvalumab does not induce antibody dependent cell-mediated cytotoxicity (ADCC). Selective blockade of PD-L1/PD-1 and PD-L1/CD80 interactions enhances antitumour immune responses and increases T-cell activation.
Original license holder
AstraZeneca
Marketing authorisation numbers
EU/1/18/1322/002
Marketing authorisation holder
AstraZeneca AB
SE-151 85 Södertälje
Sweden
Name of the manufacturer of the biological active substance
AstraZeneca Pharmaceuticals LP
Frederick Manufacturing Center (FMC)
633 Research Court
Frederick, Maryland 21703 United States
Name and address of the manufacturer(s) responsible for batch releaseMedImmune UK Ltd
6 Renaissance Way
Liverpool,
L24 9JW
United Kingdom

alternatively:

MedImmune Pharma B.V.
Lagelandseweg 78
6545CG Nijmegen,
Netherlands
Max shelf life
36 months
Storage conditions
2°C – 8°C
List of excipients
Histidine
Histidine hydrochloride monohydrate
Trehalose dihydrate
Polysorbate 80

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.